Pôsobí: protizápalovo, antioxidačne
Serrapeptáza je inzým, ktorý sa získava z larvy priadky morušovaj. Má protizápalové účinky a môže pôsobiť ako prevencia proti tvorbe krvných zrazenín, ale tieto účinky sú nespoľahlivé.
Užívanie
Štandardná dávka serrapeptázy je 10-60 mg. Mala by sa užívať 3x denne na prázdny žalúdok, to znamená 30 minút pred jedlom alebo 2 hodiny po jedle. Väčšina výskumov používa dávkovanie 10 mg každých 8 hodín. Na stanovenie optimálnej dávky bude potrebných viac výskumov na ľuďoch. 10 mg je približne ekvivalentných 20 000 enzymatickým jednotkám.
Literatúra
- Al-Khateeb TH, Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. Int J Oral Maxillofac Surg. (2008)
- Bhagat S, Agarwal M, Roy V. Serratiopeptidase: a systematic review of the existing evidence. Int J Surg. (2013)
- Badhe RV, et al. Media optimization studies for Serratiopeptidase production from Serratia marcescens ATCC 13880. Hindustan Antibiot Bull. (2009)
- Purification and characterization of four proteases from a clinical isolate of Serratia marcescens kums 3958.
- Pansuriya R, Singhal R. Effects of dissolved oxygen and agitation on production of serratiopeptidase by Serratia marcescens NRRL B-23112 in stirred tank bioreactor and its kinetic modeling. J Microbiol Biotechnol. (2011)
- CASTANEDA-AGULLO M. Studies on the biosynthesis of extracellular proteases by bacteria. I. Serratia marcescens, synthetic and gelatin media. J Gen Physiol. (1956)
- Bromke BJ, Hammel JM. Regulation of extracellular protease formation by Serratia marcescens. Can J Microbiol. (1979)
- Matsumoto K, et al. Purification and characterization of four proteases from a clinical isolate of Serratia marcescens kums 3958. J Bacteriol. (1984)
- Selan L, et al. Proteolytic enzymes: a new treatment strategy for prosthetic infections. Antimicrob Agents Chemother. (1993)
- Cloning and sequencing of Serratia protease gene.
- Easily absorbable enzyme preparation.
- Umashankar MS, Sachdeva RK, Gulati M. Aquasomes: a promising carrier for peptides and protein delivery. Nanomedicine. (2010)
- Rawat M, et al. Development and in vitro evaluation of alginate gel-encapsulated, chitosan-coated ceramic nanocores for oral delivery of enzyme. Drug Dev Ind Pharm. (2008)
- Moriya N, et al. Intestinal absorption of serrapeptase (TSP) in rats. Biotechnol Appl Biochem. (1994)
- Woodley JF. Enzymatic barriers for GI peptide and protein delivery. Crit Rev Ther Drug Carrier Syst. (1994)
- KV S, Devi GS, Mathew ST. Liposomal formulations of serratiopeptidase: in vitro studies using PAMPA and Caco-2 models. Mol Pharm. (2008)
- Camenisch G, Folkers G, van de Waterbeemd H. Shapes of membrane permeability-lipophilicity curves: extension of theoretical models with an aqueous pore pathway. Eur J Pharm Sci. (1998)
- Obata K, et al. Prediction of oral drug absorption in humans by theoretical passive absorption model. Int J Pharm. (2005)
- Nirale NM, Menon MD. Topical formulations of serratiopeptidase: development and pharmacodynamic evaluation. Indian J Pharm Sci. (2010)
- Shah MH, Paradkar A. Cubic liquid crystalline glyceryl monooleate matrices for oral delivery of enzyme. Int J Pharm. (2005)
- Kakinuma A, et al. Repression of fibrinolysis in scalded rats by administration of Serratia protease. Biochem Pharmacol. (1982)
- Kee WH, et al. The treatment of breast engorgement with Serrapeptase (Danzen): a randomised double-blind controlled trial. Singapore Med J. (1989)
- Malshe PC. A preliminary trial of serratiopeptidase in patients with carpal tunnel Syndrome. J Assoc Physicians India. (2000)
- Jadav SP, et al. Comparison of anti-inflammatory activity of serratiopeptidase and diclofenac in albino rats. J Pharmacol Pharmacother. (2010)
- Tachibana M, et al. A multi-centre, double-blind study of serrapeptase versus placebo in post-antrotomy buccal swelling. Pharmatherapeutica. (1984)
- Chopra D, et al. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain model. Int J Oral Maxillofac Surg. (2009)
- Murugesan K, Sreekumar K, Sabapathy B. Comparison of the roles of serratiopeptidase and dexamethasone in the control of inflammation and trismus following impacted third molar surgery. Indian J Dent Res. (2012)
- Panagariya A, Sharma AK. A preliminary trial of serratiopeptidase in patients with carpal tunnel syndrome. J Assoc Physicians India. (1999)
- Esch PM, Gerngross H, Fabian A. Reduction of postoperative swelling. Objective measurement of swelling of the upper ankle joint in treatment with serrapeptase– a prospective study. Fortschr Med. (1989)
- Bracale G, Selvetella L. Clinical study of the efficacy of and tolerance to seaprose S in inflammatory venous disease. Controlled study versus serratio-peptidase. Minerva Cardioangiol. (1996)
- Relevant Role of Fibronectin-Binding Proteins in Staphylococcus aureus Biofilm-Associated Foreign-Body Infections.
- Christner M, et al. The giant extracellular matrix-binding protein of Staphylococcus epidermidis mediates biofilm accumulation and attachment to fibronectin. Mol Microbiol. (2010)
- Kaplan JB. Biofilm dispersal: mechanisms, clinical implications, and potential therapeutic uses. J Dent Res. (2010)
- Artini M, et al. Comparison of the action of different proteases on virulence properties related to the staphylococcal surface. J Appl Microbiol. (2013)
- Artini M, et al. A new anti-infective strategy to reduce adhesion-mediated virulence in Staphylococcus aureus affecting surface proteins. Int J Immunopathol Pharmacol. (2011)
- Longhi C, et al. Protease treatment affects both invasion ability and biofilm formation in Listeria monocytogenes. Microb Pathog. (2008)
- Influence of interfaces on microbial activity.
- Costerton JW, et al. Bacterial biofilms in nature and disease. Annu Rev Microbiol. (1987)
- Lee HS, et al. A technique for quantitative cytology of nasal secretions. Eur Arch Otorhinolaryngol. (1991)
- Nakamura S, et al. Effect of the proteolytic enzyme serrapeptase in patients with chronic airway disease. Respirology. (2003)
- Majima Y, et al. Effects of orally administered drugs on dynamic viscoelasticity of human nasal mucus. Am Rev Respir Dis. (1990)
- Majima Y, et al. The effect of an orally administered proteolytic enzyme on the elasticity and viscosity of nasal mucus. Arch Otorhinolaryngol. (1988)
- Shimura S, et al. Effect of expectorants on relaxation behavior of sputum viscoelasticity in vivo. Biorheology. (1983)
- Mecikoglu M, et al. The effect of proteolytic enzyme serratiopeptidase in the treatment of experimental implant-related infection. J Bone Joint Surg Am. (2006)
- Ishihara Y, Kitamura S, Takaku F. Experimental studies on distribution of cefotiam, a new beta-lactam antibiotic, in the lung and trachea of rabbits. II. Combined effects with serratiopeptidase. Jpn J Antibiot. (1983)
- Aratani H, Tateishi H, Negita S. Studies on the distributions of antibiotics in the oral tissues: Experimental staphylococcal infection in rats, and effect of serratiopeptidase on the distributions of antibiotics (author’s transl). Jpn J Antibiot. (1980)
- Viswanatha Swamy AH, Patil PA. Effect of some clinically used proteolytic enzymes on inflammation in rats. Indian J Pharm Sci. (2008)
- Shimizu H, et al. A case of serratiopeptidase-induced subepidermal bullous dermatosis. Br J Dermatol. (1999)
- Mazzone A, et al. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo. J Int Med Res. (1990)